Abstract:Immune checkpoint blockade (ICB) has shown unprecedented success in improving clinical outcomes for numerous cancer patients, but many patients still fail to respond to treatment. Studies have demonstrated that the tumor microenvironment, tumor mutational burden, and patient DNA Damage Repair (DDR) deficiency may play a key role in determining response to ICB. To better characterize this and define key determinants of ICB response, we created an isogenic knockout BRCA2 in a murine 4T1 metastatic TNBC background to model these differential clinical responses and to assess how these tumor-intrinsic programs influence the tumor immune microenvironment to poise tumors for immunotherapy response. Differential immune landscapes were found via scRNAseq at baseline and with ICB driven by tumor DDR status with notable differences in the myeloid compartment and CXCR3-expressing T cell, NK, pDC, DCs, and plasma cells. Differential expression and interferon stimulated gene (ISG) metagene analysis showed notable differences in ISG expression in DDR-deficient samples at baseline, particularly in clusters containing monocytes and macrophages. Additionally, differential expression of CXCL10 in monocytes/macrophages and assessment of ligand-receptor interactions by CellChat similarly showed enhanced contribution CXCL10-CXCR3. Parallel bulk RNAseq analysis showed increased production of T cell trafficking chemokines that would poise the tumor for response to ICB. Our lab established a genetic interferon reporter system to measure both tumor intrinsic interferon-driven inflammation in cis and in trans with tumor associated macrophages, which enables multidimensional tracking of bidirectional signaling between tumor cells and macrophages by flow. This system enabled screening of inhibitors and tumor knockout cell lines to identify that tumor-intrinsic cGAS/STING and IFNb1 reinforce production of tumor and myeloid CXCL10/11 to poise the tumor for response to ICB. Further assessment of tumor cell lines via cellular fractionation experiments identified the presence of both gDNA and R-loops in the cytoplasm of BRCA2-mutant mammary cancer cell lines that may be detected as damage associated molecular patterns by tumor cells or myeloid cells in the tumor bed. Future studies aim at validating this DDR-driven production of IFNb1 as a driver of T cell chemokines in vivo; tumor-intrinsic knockout of IFNb1 and other T cell promoting chemokines (CXCL10/11/CCL5) to assess tumor or myeloid driven nature of this response to ICB and depletion of myeloid cells are being performed in parallel to assess contribution of tumor and myeloid cells, respectively. Taken together, our results have important implications for understanding the key drivers of ICB response in the tumor microenvironment and how patient-intrinsic mutations differentially poise the microenvironment for immunotherapy response. Citation Format: Natalie Vaninov, Robert Samstein. Defining the Determinants of Immune Response in DNA Homologous Recombination Deficient Tumors [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl) nr B041.

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

Abstract B041: Defining the Determinants of Immune Response in DNA Homologous Recombination Deficient Tumors

Comprehensive Analysis of Regulatory Factors and Immune-Associated Patterns to Decipher Common and BRCA1/2 Mutation-Type-Specific Critical Regulation in Breast Cancer

S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy

A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient

Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

Clinical and Molecular Features of ATM and BRCA2 Mutations in Metastatic Prostate Cancer.

Supplementary Tables S1-S4 from the BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer

Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations.

Abstract B019: Deciphering the role of homologous recombination deficiency mutations in the response to combined immune checkpoint and PARP inhibitors

Association of BRCA 1 and BRCA 2 Mutations with Survival , Chemotherapy Sensitivity , and Gene Mutator Phenotype in Patients with Ovarian Cancer

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

Abstract #4440: BRCA1 Modulates Malignant Cell Behavior, the Expression of Survivin and Chemosensitivity in Human Breast Cancer Cells

Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8 + TILs based on BRCA1/2 mutation status in epithelial ovarian cancers

BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer

Clonal tracing reveals diverse patterns of response to immune checkpoint blockade

Differentially Expressed Genes and Key Molecules of BRCA1/2-mutant Breast Cancer: Evidence from Bioinformatics Analyses.

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit

Microenvironmental factors shape resistance patterns to immune checkpoint blockade

Discussion on the Use of Taxanes for Treatment of Breast Cancers in BRCA1 Mutations Carriers